Intravenous cyclophosphamide monthly pulses in refractory myasthenia gravis.

Enrique Gomez-FigueroaSofía Garcia-TrejoLisette Bazan-RodriguezRoberto Cervantes-UribeGerman Chac-LezamaJuan Carlos López-HernándezSteven Vargas-Cañas

Published in: Journal of neurology (2019)

CYC was effective in all patients with refractory MG for a mean of 9 months, with worsening thereafter, which could be associated with low cumulative dose. The symptomatic improvement with CYC was noted within the 1st month. We conclude that CYC is effective as an induction to remission therapy, although our data suggest it is not effective as a long-term therapy.

Keyphrases

myasthenia gravis
high dose
electronic health record
stem cells
systemic lupus erythematosus
mesenchymal stem cells
cell therapy
ulcerative colitis
deep learning